[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$bivv
$bivv sees positive sentiment driving interest. Engagements and mentions are up slightly, indicating a growing community around the crypto project.
About $bivv
A cryptocurrency.
Insights #
- $bivv engagements is up XX% from the previous week.
Engagements: X #
Engagements 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: XX
1 Week: X +25%
1 Month: X -XX%
1-Year High: XXX on 2025-05-05
1-Year Low: X on 2025-06-15
| Social Network | X |
|---|---|
| Engagements | X |
Mentions: X #
Mentions 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: X
1 Month: X no change
1-Year High: X on 2025-07-03
1-Year Low: X on 2025-04-27
| Social Network | X |
|---|---|
| Mentions | X |
Creators: X #
Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning $bivv in the last XX hours which is no change from in the previous XX hours
Daily Average: X
1 Month: X no change
1-Year High: X on 2025-07-25
1-Year Low: X on 2025-04-27
Top assets mentioned In the posts about $bivv in the last XX hours
Acadia Pharmaceuticals Inc. (ACAD) Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) Intra-Cellular Therapies Inc. (ITCI) Blueprint Medicines Corporation (BPMC)
Top topics mentioned In the posts about $bivv in the last XX hours
Top Social Posts #
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Citizens reiterated $ACAD Market Outperform/$38. Re: PWS data on track to report in 4Q25: sees 20-30%(55% PoS) on +VE data; 10-15% (45% PoS)on -VE data. Citizens said in its note to investors: Phase X results for ACP-101 in Prader-Willi syndrome (PWS) expected in early 4Q25; we reiterate our Market Outperform rating and risk-adjusted DCF-derived $XX price target on Acadia Pharmaceuticals. Acadia remains on track to report top-line results in early 4Q25 from the Phase X COMPASS-PWS trial evaluating ACP-101 to treat hyperphagia in patients with Prader-Willi syndrome. COMPASS-PWS has been"
X Link @Quantumup1 2025-09-19T12:21Z 3826 followers, 1854 engagements